Inicio>>Signaling Pathways>> Tyrosine Kinase>> EGFR>>O-Desmethyl Gefitinib

O-Desmethyl Gefitinib

Catalog No.GC44491

O-desmetil gefitinib es un metabolito activo de gefitinib en plasma humano. La formaciÓn de O-desmetil gefitinib depende de la actividad de CYP2D6. O-desmetil gefitinib inhibe EGFR con una IC50 de 36 nM en ensayos subcelulares.

Products are for research use only. Not for human use. We do not sell to patients.

O-Desmethyl Gefitinib Chemical Structure

Cas No.: 847949-49-9

Tamaño Precio Disponibilidad Cantidad
500μg
20,00 $
Disponible
1mg
29,00 $
Disponible
5mg
116,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

O-Desmethyl gefitinib is the major metabolite of gefitinib in human plasma, formed by the cytochrome P450 isoform CYP2D6. It is an active metabolite that inhibits EGFR similarly to gefitinib in subcellular assays (IC50s = 36 and 22 nM, respectively) but is less active in whole cell assays (IC50s = 760 and 49 nM, respectively). In a LoVo tumor mouse xenograft model, the tumor concentration of O-desmethyl gefitinib was 6.8-fold lower than that of gefitinib and did not significantly reduce tumor growth. A high plasma concentration of O-desmethyl gefitinib in patients homozygous for CYP2D6 was not associated with an increase in adverse effects.

Reseñas

Review for O-Desmethyl Gefitinib

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for O-Desmethyl Gefitinib

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.